Evidence map›Paper›PMID 36389285›Full record

ArticleCytotechnology2022

A novel matrine derivative, WM130, inhibits activation and movement of human hepatic stellate LX-2 cells by targeting cofilin 1.

Yang Xu, Jicheng Duan, Weidan Ji, Chao Liu, Xiang Li, Qiuye Wu, Chunfang Gao, Changqing Su

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cytotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Yang Xu *Clinical Laboratory Medicine Center, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437 China.
Jicheng Duan *Department of Molecular Oncology, Eastern Hepatobiliary Surgery Hospital and National Center of Liver Cancer, Navy Military Medical University, Shanghai, 200438 China.
Weidan JiDepartment of Molecular Oncology, Eastern Hepatobiliary Surgery Hospital and National Center of Liver Cancer, Navy Military Medical University, Shanghai, 200438 China.
Chao LiuDepartment of Pharmacy, Navy Military Medical University, Shanghai, 200438 China.
Xiang LiDepartment of Pharmacy, Navy Military Medical University, Shanghai, 200438 China.
Qiuye WuDepartment of Pharmacy, Navy Military Medical University, Shanghai, 200438 China.
Chunfang GaoClinical Laboratory Medicine Center, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437 China.
Changqing SuDepartment of Molecular Oncology, Eastern Hepatobiliary Surgery Hospital and National Center of Liver Cancer, Navy Military Medical University, Shanghai, 200438 China.
Second Military Medical University · CNYueyang Hospital · CNEastern Hepatobiliary Surgery Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Matrine Supplementary Information: The online version contains supplementary material available at 10.1007/s10616-022-00548-w.

Indexed as

Cofilin 1Hepatic stellate cellsLiver fibrosisLX-2 cell lineNovel matrine derivative WM130

Identifiers

PMID36389285
PMCPMC9652194
OpenAlexW4293434838

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.